prog - PROG STOCK NEWS

Progenity, Inc. (Nasdaq: PROG) announced the appointment of Jill Howe to its board of directors as of November 3, 2021. Howe will also serve as chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Interim CEO Eric d’Esparbes highlighted Howe's extensive pharmaceutical industry experience, which is expected to enhance Progenity's financial leadership during its strategic transformation. Howe's background includes roles at DTxPharma and Gossamer Bio, with over 20 years of experience in biotechnology finance.

Progenity, Inc. (NASDAQ: PROG) will announce its third quarter 2021 financial results on November 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide updates. Progenity focuses on innovative biotechnology solutions in women’s health, gastrointestinal health, and oral biotherapeutics, using a multi-omics approach to enhance disease diagnostics and patient care.

Progenity (Nasdaq: PROG) has entered into private agreements to exchange $20.175 million of its 7.25% convertible senior notes due 2025 for approximately 8.51 million shares of common stock. This exchange reduces the company's non-affiliated debt by about 38%. Following the exchange, $137.125 million in notes will remain outstanding, with $103.5 million held by Athyrium Capital Management. Additionally, Progenity will issue about 427,804 shares to certain investors for waiving lock-up provisions related to previous securities offerings.

Progenity, a biotechnology company trading on Nasdaq under the symbol PROG, announced its participation in the IBD Innovate Product Development conference for Crohn’s & Colitis on November 18-19, 2021. Chris Wahl, VP of Strategy and Operations, will present on Novel Drug Delivery Technologies, focusing on its innovative Drug Delivery System (DDS) aimed at enhancing treatment for ulcerative colitis. The DDS targets therapeutic delivery, minimizing toxicity. Progenity is in preclinical development of drug candidates PGN-001 and PGN-600, with clinical studies slated for 2022.

Progenity (Nasdaq: PROG) announced the issuance of four new patents by the USPTO, focusing on its ingestible technologies for therapeutic delivery via the gastrointestinal tract. Key highlights include U.S. Patent No. 11,007,356 for an ingestible device aimed at systemic drug delivery, and U.S. Patent No. 11,033,490 for a JAK inhibitor targeting ulcerative colitis treatment. The company's Oral Biotherapeutic Delivery System (OBDS) has shown bioavailability of up to 44% for proteins. Progenity’s patent portfolio now includes 180 issued patents, reinforcing its innovation in biotherapeutics.

Progenity, Inc. (Nasdaq: PROG) has successfully closed a registered direct offering, selling 13,333,334 shares of common stock at $1.50 each for gross proceeds of approximately $20 million. The offering was priced at a premium to market under Nasdaq regulations. The funds from this offering will be used to support Progenity's operations, enhance its research and development in diagnostic technologies, and for additional working capital. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering.

Progenity, Inc. (Nasdaq: PROG) has announced a registered direct offering of 13,333,334 shares of its common stock at $1.50 per share, projected to close around October 6, 2021. The offering aims to raise approximately $20 million, which will support operations and fund research and development related to its diagnostic technologies and precision medicine platform. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The shares are registered under a previously effective shelf registration statement with the SEC.

Progenity, Inc. (Nasdaq: PROG) will participate in the 11th Annual Partnership Opportunities in Drug Delivery (PODD) Conference on October 28-29, 2021, in Boston. Chris Wahl, VP of Strategy and Operations, will join a panel discussing orally ingestible devices for delivering biologics. Progenity's Oral Biotherapeutic Delivery System (OBDS) aims to provide needle-free delivery of large molecules, enhancing bioavailability and potential efficacy. The company continues to secure partnerships for OBDS, including recent agreements with Ionis Pharmaceuticals and two leading pharmaceutical firms.

Progenity, Inc. (Nasdaq: PROG) announced the issuance of U.S. Patent No. 11,112,403 related to methods for detecting preeclampsia through assays measuring placental growth factor (PlGF). The patent enhances Progenity's ability to commercialize the Preecludia™ test, targeting a $3 billion market. Dr. Matthew Cooper highlighted the significance of distinguishing PlGF forms in assessments. The company has completed clinical validation studies, supporting potential partnerships for the test aimed at improving maternal health outcomes.